16250-08-1

Basic information

• Product Name: 2-AMINOPYRIDINE-5-SULFONIC ACID
• Synonyms: 6-Amino-3-pyridinesulfonic Acid;Pyridin-2-amino-5-sulfonic Acid;Pyridine-2-amino-5-sulfonic Acid;2-Aminopyridine-5-sulphonic acid, 2-Amino-5-sulphopyridine;6-Aminopyridine-3-sulphonic acid;2-AMINOPYRIDINE-5-SULFONIC ACID;2-AMINOPYRIDINE-5-SULPHONIC ACID;6-AMINOPYRIDINE-3-SULFONIC ACID
• CAS NO: 16250-08-1
• Molecular Formula: C5H6N2O3S
• Molecular Weight: 174.18
• Product Categories: Aromatics Compounds;Aromatics;Bases & Related Reagents;Nucleotides;Sulfur & Selenium Compounds;Pyridines
• Mol File: 16250-08-1.mol
• Article Data: 11

Chemical Properties

• Melting Point: >300°C
• Appearance: Off-white solid
• Density: 1.617
• Refractive Index: 1.634
• Storage Temp.: -20°C Freezer
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: -1?+-.0.50(Predicted)
• CAS DataBase Reference: 2-AMINOPYRIDINE-5-SULFONIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-AMINOPYRIDINE-5-SULFONIC ACID(16250-08-1)
• EPA Substance Registry System: 2-AMINOPYRIDINE-5-SULFONIC ACID(16250-08-1)

Safety Data

• Hazardous Substances Data: 16250-08-1(Hazardous Substances Data)

Usage

Chemical Properties

Off-Whie Solid

InChI:InChI=1/C5H6N2O3S/c6-5-2-1-4(3-7-5)11(8,9)10/h1-3H,(H2,6,7)(H,8,9,10)

Upstream product

• 504-29-0 2-aminopyridine 

Downstream Products

• 108922-18-5 6-(4-methyl-3-nitro-benzoylamino)-pyridine-3-sulfonic acid 
• 247582-62-3 2-Amino-3-bromopyridine-5-sulphonic Acid 
• 62009-38-5 6-amino-5-nitropyridine-3-sulfonic acid 
• 718599-83-8 2-phenylazopyridine-5-sulfonic acid 
• 216394-05-7 5-bromo-6-chloropyridine-3-sulfonyl chloride 
• 247582-73-6 2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridine-3-carboxylic Acid 
• 111240-88-1 6-[4-methyl-3-(3-nitro-benzoylamino)-benzoylamino]-pyridine-3-sulfonic acid 
• 108625-65-6 N,N'-bis-{3-[2-methyl-5-(5-sulfo-[2]pyridylcarbamoyl)-phenylsulfamoyl]-phenyl}-urea 
• 111473-54-2 6-[4-methyl-3-(3-nitro-benzenesulfonylamino)-benzoylamino]-pyridine-3-sulfonic acid 
• 109733-64-4 6-[3-(3-amino-benzenesulfonylamino)-4-methyl-benzoylamino]-pyridine-3-sulfonic acid 
• 110395-68-1 6-[3-(3-amino-benzoylamino)-4-methyl-benzoylamino]-pyridine-3-sulfonic acid 
• 108539-83-9 6-(3-amino-4-methyl-benzoylamino)-pyridine-3-sulfonic acid 
• 100517-08-6 5,6-diamino-pyridine-3-sulfonic acid 

Relevant articles and documents

The discovery of UK-369003, a novel PDE5 inhibitor with the potential for oral bioavailability and dose-proportional pharmacokinetics

This paper describes our recent efforts to design and synthesise potent and selective PDE5 inhibitors and the use of in vitro predictors of clearance, absorption and permeability to maximise the potential for dose-proportional pharmacokinetics and good oral bioavailability in man. Optimisation of the preclinical profile resulted in the identification of UK-369003 (19a) and its nomination as a clinical candidate. The clinical pharmacokinetic and safety profile has enabled us to progress the compound to test its efficacy in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) and a paper describing its efficacy has recently been published.2,3.

Treatment of diabetic ulcers

This invention relates to the use of cyclic guanosine 3′, 5′-monophosphate phosphodiesterase type five (cGMP PDE5) inhibitors, including in particular the compound sildenafil, for the treatment of diabetic ulcers, particularly diabetic foot ulcers.

Methods of treatment and kits comprising a growth hormone secretagogue

The present invention relates to methods of treating bulimia nervosa, male erectile dysfunction, female sexual dysfunction, thyroid cancer, breast cancer, or ameliorating ischemic nerve or muscle damage. The present invention also relates to kits that can be used in the treatment of bulimia nervosa, male erectile dysfunction, female sexual dysfunction, thyroid cancer, breast cancer, or ameliorating ischemic nerve or muscle damage. The present invention further relates to increasing gastrointestinal motility after surgery and increasing gastrointestinal motility in patients who have been administered an agent that decreases gastrointestinal motility.